7X91
The SARS-CoV-2 receptor binding domain bound with an Fv-clasp form of a human neutralizing antibody Ab496
Summary for 7X91
| Entry DOI | 10.2210/pdb7x91/pdb |
| EMDB information | 33063 |
| Descriptor | Spike glycoprotein, An Fv-clasp version of the Ab496 heavy chain, An Fv-clasp version of the Ab496 light chain, ... (4 entities in total) |
| Functional Keywords | severe acute respiratory syndrome coronavirus-2 (sars-cov-2) spike trimer, covid-19, human neutralizing antibody, rbd, viral protein |
| Biological source | Severe acute respiratory syndrome coronavirus 2 More |
| Total number of polymer chains | 3 |
| Total formula weight | 186196.33 |
| Authors | Kamada, K.,Shirouzu, M. (deposition date: 2022-03-15, release date: 2022-12-07, Last modification date: 2024-10-09) |
| Primary citation | Takeshita, M.,Fukuyama, H.,Kamada, K.,Matsumoto, T.,Makino-Okamura, C.,Uchikubo-Kamo, T.,Tomabechi, Y.,Hanada, K.,Moriyama, S.,Takahashi, Y.,Ishigaki, H.,Nakayama, M.,Nguyen, C.T.,Kitagawa, Y.,Itoh, Y.,Imai, M.,Maemura, T.,Furusawa, Y.,Ueki, H.,Iwatsuki-Horimoto, K.,Ito, M.,Yamayoshi, S.,Kawaoka, Y.,Shirouzu, M.,Ishii, M.,Saya, H.,Kondo, Y.,Kaneko, Y.,Suzuki, K.,Fukunaga, K.,Takeuchi, T. Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models. Iscience, 25:105596-105596, 2022 Cited by PubMed Abstract: The use of therapeutic neutralizing antibodies against SARS-CoV-2 infection has been highly effective. However, there remain few practical antibodies against viruses that are acquiring mutations. In this study, we created 494 monoclonal antibodies from patients with COVID-19-convalescent, and identified antibodies that exhibited the comparable neutralizing ability to clinically used antibodies in the neutralization assay using pseudovirus and authentic virus including variants of concerns. These antibodies have different profiles against various mutations, which were confirmed by cell-based assay and cryo-electron microscopy. To prevent antibody-dependent enhancement, N297A modification was introduced. Our antibodies showed a reduction of lung viral RNAs by therapeutic administration in a hamster model. In addition, an antibody cocktail consisting of three antibodies was also administered therapeutically to a macaque model, which resulted in reduced viral titers of swabs and lungs and reduced lung tissue damage scores. These results showed that our antibodies have sufficient antiviral activity as therapeutic candidates. PubMed: 36406861DOI: 10.1016/j.isci.2022.105596 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (4.3 Å) |
Structure validation
Download full validation report
